FORM PTO-1449

Att. Docket No.: REG 142-C

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN:

09/577,468

Applicant:

Wong, et al.

Date Filed:

May 24, 2000

Title: USE OF MODIFIED CILIARY

NEUROTROPHIC FACTOR

Examiner:

R. Clinton

Group Art Unit: 1647

April 23, 2003

Number

U.S. PATENT DOCUMENTS

Examiner Initials

Patent Number Issue Date Publication Publication

Date

RECEIVED

MAY 0 6 2003

ECH CENTER 1600/2900

Name

FOREIGN PATENT DOCUMENTS

Examiner Initials

Document Number

Date

Country

Class/ Subclass Translation

Yes No

WO98/22128_5/28/1998 PCT

EP 1010432A1 6/21/2000 Europe

WO91/04316 4/4/1991 PCT

WO91/19009 12/12/1991PCT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

RON

Miller, R.G., et al, Annals of Neurology (1996) Vol.39,No. 2, pp. 256-260, XP008005507, "A placebo-controlled trail of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis."

Miller, R.G., et al, Neurology (1996), Vol. 47, No. 5, pp. 1329-1331, XP001064801, "Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis."

Mayer 9/23/03